Vivanza Biosciences Delays Q2 FY27 Board Meeting to November 6

Vivanza Biosciences Limited has postponed its board meeting for approval of Q2 FY27 and H1 FY27 unaudited results from November 3 to November 6, 2026, citing unavoidable circumstances. The meeting will consider financial statements and limited review reports for the quarter and half-year ended September 30, 2026.

Why did Vivanza Biosciences postpone its Q2 FY27 board meeting?

Vivanza Biosciences said the board meeting originally scheduled for November 3, 2026, has been rescheduled to November 6, 2026, due to unavoidable circumstances. The company made the disclosure under Regulations 29 and 30 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015.

The board will meet at the company’s registered office in Ahmedabad. Its stated agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, along with the limited review report.

The available disclosure does not specify the nature of the circumstances behind the postponement. It also does not disclose any change in the reporting period, financial-result scope, or venue other than the revised meeting date.

The rescheduling follows an October 28 intimation in which Vivanza Biosciences had said its board would meet on November 3 to consider the September-quarter and half-year results. The revised date moves the proposed consideration by three days.

What will the November 6 board meeting consider?

The November 6 meeting is scheduled to consider unaudited standalone and consolidated results for Q2 FY27 and H1 FY27. These accounts cover the three months and six months ended September 30, 2026, respectively, and will be accompanied by a limited review report.

A limited review is part of the quarterly reporting process for listed companies. The company has also stated that disclosure under Regulation 23(9), which relates to related-party transactions, is not applicable for Q2 FY27.

The announcement concerns the timing of the board meeting rather than the financial outcome. Vivanza Biosciences had not disclosed its September-quarter revenue, profit, margins, or earnings per share in the material provided. Investors will need to wait for the result announcement following the board’s consideration.

The company’s prior FY27 quarterly reporting process included an Audit Committee review before the board approved Q1 results on August 7, 2026. The unaudited Q1 FY27 results were subsequently submitted to the Bombay Stock Exchange on August 8, 2026.

What was Vivanza Biosciences' latest reported financial performance?

Vivanza Biosciences reported consolidated net sales of ₹9.29 crore for the quarter ended June 30, 2026, compared with ₹8.94 crore in the corresponding quarter a year earlier. The company reported quarterly net profit of ₹0.15 crore, up from ₹0.09 crore in Q1 FY26, while EBITDA rose to ₹0.30 crore from ₹0.16 crore.

The reported earnings per share for Q1 FY27 was ₹0.04, compared with ₹0.02 in Q1 FY26. Separately presented quarterly data listed revenue of ₹9.14 crore and net profit of ₹0.15 crore for June 2026. The source material also lists sales of ₹9.29 crore, so investors should refer to the company’s filed standalone and consolidated statements for the applicable line-item definitions.

For FY26, Vivanza Biosciences reported revenue of ₹112.23 crore and net profit of ₹0.38 crore. The corresponding net profit margin was 0.33%, based on the figures provided, indicating that profit remained small relative to annual revenue.

How does the trading-window closure affect investors and insiders?

Vivanza Biosciences closed its trading window for dealing in its securities from October 1, 2026, until 48 hours after declaration of the September-quarter unaudited results. The closure applies to designated persons and connected persons under the company’s insider-trading compliance framework.

The trading-window restriction is intended to limit trading by individuals who could have access to unpublished price-sensitive information before financial results are released. It does not mean that ordinary market trading in the company’s listed shares has been suspended.

For investors, the relevant near-term event is the release of the Q2 FY27 and H1 FY27 results after the board meeting. The postponement itself provides no updated guidance on revenue, profitability, business expansion, or other operational targets.

The company has used the same reporting framework for earlier periods. Its board approved audited standalone and consolidated financial results for FY26, ended March 31, 2026, and later approved unaudited standalone and consolidated results for the June 2026 quarter.

Conclusion

Vivanza Biosciences has deferred its board meeting by three days, from November 3 to November 6, while retaining the agenda of approving Q2 FY27 and H1 FY27 unaudited standalone and consolidated results. The company’s latest reported quarter showed consolidated net sales of ₹9.29 crore and net profit of ₹0.15 crore for June 2026.

The next item to watch is the company’s result disclosure after the November 6 board meeting, including the limited review report and the end of the trading-window closure 48 hours after results are declared. The provided disclosures do not set out financial guidance or an operational target for the September quarter.